The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

A computer implemented method of diagnosing whether a human subject is infected with Zika virus, includes: determining a correlation between a fundus test image of an eye of the human subject for presence of gross macular pigment mottling with a known set of Zika virus infected fundus images and with a known set of healthy fundus images, wherein a high correlation/low correlation between the fundus test image and the known set of Zika virus infected fundus images indicates that there is a high probability/low probability that the human subject is infected with Zika virus, wherein a high correlation/low correlation between the fundus test image and the known set of healthy fundus images indicates that there is a low probability/high probability that the human subject is infected with Zika virus.

A computer implemented method of diagnosing whether a human subject is infected with Zika virus, includes: determining a correlation between a fundus test image of an eye of the human subject for presence of gross macular pigment mottling with a known set of Zika virus infected fundus images and with a known set of healthy fundus images, wherein a high correlation/low correlation between the fundus test image and the known set of Zika virus infected fundus images indicates that there is a high probability/low probability that the human subject is infected with Zika virus, wherein a high correlation/low correlation between the fundus test image and the known set of healthy fundus images indicates that there is a low probability/high probability that the human subject is infected with Zika virus.

The invention relates to a peptide capable of activating NK cell-mediated immunity, the peptide comprising or consisting of the amino acid sequence XnAX2X1, Wherein Xn is an amino acid sequence of between 5 and 12 residues, and X1 is any amino acid; or leucine or phenylalanine; and X2 is alanine, threonine or serine. The invention further relates to an MHC class I molecule and the peptide, nucleic acids encoding the peptide, activated NK cells, and related compositions and methods, including use in methods of treatment.

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.